The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome
about
An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered MicrobiomeThe role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatmentsMechanism-Oriented Therapy of Irritable Bowel SyndromeNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsIrritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentInflammation in irritable bowel syndrome: Myth or new treatment target?Mast Cells and Irritable Bowel Syndrome: From the Bench to the BedsideImmunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature reviewIntestinal secretory mechanisms in irritable bowel syndrome-diarrheaIntestinal permeability--a new target for disease prevention and therapyBrain-gut axis: from basic understanding to treatment of IBS and related disordersOverlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonistsIBS and the role of otilonium bromide.Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significanceRecent advances in pharmacological treatment of irritable bowel syndrome.The role of mast cells in functional GI disorders.The Expression of Serum Antibodies Against Gonadotropin-releasing Hormone (GnRH1), Progonadoliberin-2, Luteinizing Hormone (LH), and Related Receptors in Patients with Gastrointestinal Dysfunction or Diabetes Mellitus.The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota.Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis.Functional abdominal pain and irritable bowel syndrome in children and adolescents.Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome.Increased VGLUT3 involved in visceral hyperalgesia in a rat model of irritable bowel syndrome.Lessons Learnt from Post-Infectious IBS.Mast Cell-dependent Mesenteric Afferent Activation by Mucosal Supernatant From Different Bowel Segments of Guinea Pigs With Post-infectious Irritable Bowel Syndrome.Irritable bowel syndrome - An inflammatory disease involving mast cells.Evidence-based clinical practice guidelines for irritable bowel syndrome.Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls.Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial.Recent developments in the pathophysiology of irritable bowel syndrome.Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivityDose Irritable Bowel Syndrome and Dysmotility Have an Autoimmune Origin? (Neurogastroenterol Motil 2011;23:1000-1006, e459).Serum and colonic mucosal immune markers in irritable bowel syndromeEssential role of mast cells in the visceral hyperalgesia induced by T. spiralis infection and stress in rats.Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome.Evaluating the Anti-nociceptive and Anti-inflammatory Effects of Ketotifen and Fexofenadine in Rats.Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.IBS and IBD - separate entities or on a spectrum?
P2860
Q24630575-13880D35-7219-4AB2-B575-5C65ECCDE373Q26739291-659500CC-7DA4-4477-802E-777A1D03CB37Q26747875-432686D4-4C22-4911-90AA-C2CD530D41D7Q26748617-6C79AC1B-055B-4E55-8843-A761D4F927A6Q26751193-BBB6EF17-CE15-4EEF-8F17-204367AA09A1Q26768545-0D464C78-CFB0-4876-9751-BF7E9D00EC21Q26769635-78B93EAC-D589-41E9-A193-73A3DC5D5964Q26795564-81F2FA5A-253C-4842-8691-909D2565A9B0Q26853285-D5E6C868-8E37-4502-90DD-417443B18989Q27015884-88537A82-453F-4B37-A226-92295E50D33DQ27024801-C34B91FA-883A-4B43-8981-A693727F588BQ30447974-5B9EA490-CFC7-4B32-B9F2-2A260BA96E63Q31119613-F6055BB6-31FD-4460-827D-C0A9DBECF2A8Q33456428-D9EBF0F4-8DA0-4A92-9D34-3B17361BEF5EQ33802912-27031E0B-C65E-4662-A343-C19AB1AEBD0EQ33958853-4180FBF6-82B5-4719-A102-48CE65DB2157Q34486007-2C21FA82-DE14-4409-B0E8-1B4BACC66B47Q34488937-74C97345-19F7-4255-A174-24BC1C1EFE53Q34596449-43EA8B35-D2B0-4D71-BF10-96C172B7FF37Q34654055-EBBF2A75-2BE6-4384-AF4A-206B9965C648Q35079445-FFD199AB-308A-46BC-AAAC-390AC451A945Q35095269-3C7B5D77-2CE1-4438-9FDB-6A5B2164EA4DQ35169340-561E971E-08A7-456D-A93C-398D4FB791DDQ35176122-3E08BBEA-1BE6-4EB5-841B-42909EE8C9B2Q35430640-15A1F130-59DB-4A0E-8587-69326D2B2DBAQ35502339-38E2BAB3-E4D5-4A05-804A-02868CF62188Q35513973-8FA26B00-7CD4-40E7-A5A0-13FECB3C3877Q35562079-A7987C52-F31E-4F29-83BA-14DCD313764DQ35563612-3B06A094-306B-4670-9F85-5821E20F11CAQ35689193-D33DF8D8-B150-4D8F-950F-719E8CAC6472Q35690567-2B7C9E8B-2207-4D2E-9596-21593BD4381EQ35730413-3F1761DC-2054-4351-9712-1917C7BA1F47Q35815638-9DC1956C-C2CB-415D-B72C-EE972097297CQ35865269-A827DEF4-9DBB-4129-86BE-E5FC4C0EE5A0Q35867820-CF5AC9B1-8BF9-4652-A1F5-F05E45C3B34BQ35895241-4251F5DB-D4FA-4F8E-9C8F-08F29F96456CQ35971357-28CFF6D6-F242-40E7-89E5-43C777F9D0DEQ35994064-18706BB0-4BFA-4AA3-9FAC-269A4B7590EBQ36021269-2FFA723D-ED5F-40A3-BCFF-1EE82A520C56Q36144375-922DB4B2-C040-4C05-849D-458883677F17
P2860
The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@ast
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@en
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@nl
type
label
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@ast
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@en
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@nl
prefLabel
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@ast
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@en
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@nl
P2093
P3181
P356
P1433
P1476
The mast cell stabiliser ketot ...... with irritable bowel syndrome
@en
P2093
Breg Braak
Guy E Boeckxstaens
Karin E Koopman
Mira M Wouters
Olaf Welting
Rene M van den Wijngaard
Sicco van der Heide
Stephan C Bischoff
Tamira K Klooker
P304
P3181
P356
10.1136/GUT.2010.213108
P407
P577
2010-09-01T00:00:00Z